Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

MMV joins Pool for Open Innovation against neglected tropical diseases

MMV joins Pool for Open Innovation against neglected tropical diseases

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis second-quarter pro forma net operating loss increases to $15.5 million

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme, Isis announce results of two mipomersen phase 3 studies

Alnylam second-quarter revenues increase to $26.6 million

Alnylam second-quarter revenues increase to $26.6 million

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme second-quarter revenue decreases to $1.08 billion

Abortion fight again heats up over high-risk pools, other health reform news

Abortion fight again heats up over high-risk pools, other health reform news

New findings show why some people suffer from high levels of triglycerides

New findings show why some people suffer from high levels of triglycerides

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Pfizer's new chewable Lipitor for children receives European Commission approval

Pfizer's new chewable Lipitor for children receives European Commission approval

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Update on Regulus and sanofi-aventis collaboration

Update on Regulus and sanofi-aventis collaboration

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.